Exelixis
EXEL
#1649
Rank
NZ$17.96 B
Marketcap
$64.17
Share price
5.02%
Change (1 day)
91.42%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Market capitalization of Exelixis (EXEL)

Market cap: NZ$17.96 Billion

As of February 2025 Exelixis has a market cap of NZ$17.96 Billion. This makes Exelixis the world's 1649th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.

Market cap history of Exelixis from 2000 to 2025

End of year Market Cap

Year Marketcap Change
2025NZ$17.96 B4.91%
2024NZ$17.12 B45.13%
2023NZ$11.79 B44.76%
2022NZ$8.14 B-3.76%
2021NZ$8.46 B-1.88%
2020NZ$8.62 B8.56%
2019NZ$7.94 B-9.6%
2018NZ$8.79 B-30.56%
2017NZ$12.66 B102.93%
2016NZ$6.24 B232.2%
2015NZ$1.87 B421.77%
2014NZ$0.36 B-73.85%
2013NZ$1.37 B34.89%
2012NZ$1.02 B24.08%
2011NZ$0.82 B-29.28%
2010NZ$1.16 B6.21%
2009NZ$1.09 B19.88%
2008NZ$0.91 B-22.59%
2007NZ$1.18 B-3.77%
2006NZ$1.22 B6.68%
2005NZ$1.14 B15.13%
2004NZ$0.99 B29.13%
2003NZ$0.77 B-14.82%
2002NZ$0.90 B-59.61%
2001NZ$2.24 B45.72%
2000NZ$1.54 B

End of Day market cap according to different sources

On Feb 21st, 2025 the market cap of Exelixis was reported to be:

NZ$17.96 Billion
by Nasdaq info icon info icon
NZ$17.96 Billion
by CompaniesMarketCap info icon info icon
NZ$17.96 Billion
by Yahoo Finance info icon info icon

Market capitalization for similar companies or competitors

Name Marketcap Market cap differencediff. Country
NZ$130.22 B 625.02%๐Ÿ‡ฌ๐Ÿ‡ง UK
NZ$237.78 B 1,223.89%๐Ÿ‡ซ๐Ÿ‡ท France
NZ$394.28 B 2,095.18%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$197.30 B 998.51%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$283.47 B 1,478.29%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$680.50 B 3,688.75%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$259.55 B 1,345.10%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$45.71 M-99.75%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.90 B-94.94%๐Ÿ‡บ๐Ÿ‡ธ USA